MXPA04010174A - Composicion de dispersion solida. - Google Patents

Composicion de dispersion solida.

Info

Publication number
MXPA04010174A
MXPA04010174A MXPA04010174A MXPA04010174A MXPA04010174A MX PA04010174 A MXPA04010174 A MX PA04010174A MX PA04010174 A MXPA04010174 A MX PA04010174A MX PA04010174 A MXPA04010174 A MX PA04010174A MX PA04010174 A MXPA04010174 A MX PA04010174A
Authority
MX
Mexico
Prior art keywords
solid dispersion
dispersion composition
pyridazin
methylthio
chlorophenyl
Prior art date
Application number
MXPA04010174A
Other languages
English (en)
Inventor
Yasuo Shinoda
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MXPA04010174A publication Critical patent/MXPA04010174A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Una composicion de dispersion solida caracterizada porque contiene 2-bencil -5-(4- clorofenil)- 6-[4- (metiltio) fenil]- 2H-piridazin -3-ona, hidroxipropilmetil celulosa, y polioxietilen polioxipropilen glicol; la composicion de dispersion solida se disuelve excelentemente en agua y una concentracion de 2-bencil -5- (4-clorofenil) -6-[4- (metiltio) fenil] -2H -piridazin- 3-ona que se ha disuelto, se mantiene por un cierto periodo de tiempo; de esta manera, el compuesto tiene una absorbabidad mejorada en la sangre.
MXPA04010174A 2002-04-16 2003-04-15 Composicion de dispersion solida. MXPA04010174A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37241602P 2002-04-16 2002-04-16
PCT/JP2003/004762 WO2003086405A1 (fr) 2002-04-16 2003-04-15 Composition de dispersion solide

Publications (1)

Publication Number Publication Date
MXPA04010174A true MXPA04010174A (es) 2005-02-03

Family

ID=29250849

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04010174A MXPA04010174A (es) 2002-04-16 2003-04-15 Composicion de dispersion solida.

Country Status (22)

Country Link
US (1) US6753330B2 (es)
EP (1) EP1495759A4 (es)
JP (1) JP4295629B2 (es)
KR (1) KR20040101437A (es)
CN (1) CN1291719C (es)
AU (1) AU2003235156B2 (es)
BR (1) BR0309212A (es)
CA (1) CA2481595A1 (es)
EA (1) EA007153B1 (es)
HK (1) HK1082669A1 (es)
HR (1) HRP20040959A2 (es)
IL (2) IL164206A0 (es)
IS (1) IS7488A (es)
MX (1) MXPA04010174A (es)
MY (1) MY128945A (es)
NO (1) NO20044337L (es)
NZ (1) NZ535541A (es)
PL (1) PL372980A1 (es)
TW (1) TWI319772B (es)
UA (1) UA79610C2 (es)
WO (1) WO2003086405A1 (es)
ZA (1) ZA200407657B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096281A1 (ja) * 2003-04-29 2004-11-11 Kowa Co., Ltd. 溶出性に優れた超難水溶性薬物含有組成物及びその製造法
US20070021418A1 (en) * 2003-07-30 2007-01-25 Kowa Co., Ltd. Method of inhibiting production of osteopontin
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition
JP2006001859A (ja) * 2004-06-16 2006-01-05 Shiseido Co Ltd 絆創膏組成物
US20090005384A1 (en) * 2005-01-25 2009-01-01 Kowa Co., Ltd Method for Producing Adsorptive Porous Body
CN101242831A (zh) * 2005-08-31 2008-08-13 兴和株式会社 类风湿性关节炎的预防和/或治疗方法
WO2008064259A2 (en) * 2006-11-21 2008-05-29 Biokey, Inc. Solid dispersion composition comprising fluvastatin
JP2009155282A (ja) * 2007-12-27 2009-07-16 Kowa Co 固体分散体含有医薬組成物
DE102008047910A1 (de) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
WO2019241077A1 (en) * 2018-06-11 2019-12-19 Abon Pharmaceuticals Llc. Oral eliglustat transmucosal delivery system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019239A1 (fr) * 1994-12-21 1996-06-27 Yamanouchi Pharmaceutical Co., Ltd. Composition solide a solubilite et absorbabilite ameliorees
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
JP3335132B2 (ja) * 1997-11-19 2002-10-15 興和株式会社 新規ピリダジン誘導体及びこれを有効成分とする医薬
EP2017266A1 (en) * 1997-11-19 2009-01-21 Kowa Co., Ltd. Pyridazine derivatives and medicines containing the same as effective ingredients
BR0014469A (pt) * 1999-10-04 2002-06-11 Asahi Chemical Ind Processo para melhorar a solubilidade de um derivado de amino álcool tricìclico, composição farmacêutica, processo para preparar a mesma, e, derivado de amino álcool tricìclico
JP2004131393A (ja) * 2002-10-08 2004-04-30 Kowa Co 易溶出性製剤

Also Published As

Publication number Publication date
HK1082669A1 (en) 2006-06-16
IL164206A0 (en) 2005-12-18
NO20044337L (no) 2004-10-12
IS7488A (is) 2004-10-04
TW200408671A (en) 2004-06-01
MY128945A (en) 2007-03-30
EA200401377A1 (ru) 2005-06-30
CN1646128A (zh) 2005-07-27
HRP20040959A2 (en) 2004-12-31
UA79610C2 (en) 2007-07-10
AU2003235156B2 (en) 2007-07-05
WO2003086405A1 (fr) 2003-10-23
JPWO2003086405A1 (ja) 2005-08-18
AU2003235156B9 (en) 2003-10-27
IL164206A (en) 2008-04-13
PL372980A1 (en) 2005-08-08
BR0309212A (pt) 2005-02-09
NZ535541A (en) 2006-09-29
JP4295629B2 (ja) 2009-07-15
TWI319772B (en) 2010-01-21
AU2003235156A1 (en) 2003-10-27
KR20040101437A (ko) 2004-12-02
EP1495759A1 (en) 2005-01-12
EP1495759A4 (en) 2010-12-29
US20040019122A1 (en) 2004-01-29
CN1291719C (zh) 2006-12-27
CA2481595A1 (en) 2003-10-23
ZA200407657B (en) 2006-07-26
EA007153B1 (ru) 2006-08-25
US6753330B2 (en) 2004-06-22

Similar Documents

Publication Publication Date Title
MXPA04010174A (es) Composicion de dispersion solida.
DE60224189D1 (de) Dipeptidylpeptidase-hemmer zur behandlung von diabetes
NO20024891L (no) Farmasöytiske sammensetninger
MXPA05009063A (es) Compuestos de aminoheteroarilo como inhibidores de proteina cinasa.
RS51106B (sr) Derivati prolina i njihova upotreba kao inhibitora dipeptidil peptidaze iv
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
NL350053I1 (nl) Bixafen
RS53600B1 (en) UNITS, PREPARATIONS AND METHODS
HK1197656A1 (zh) 糖原累積病 型的療法
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
HRP20050287A2 (en) Indole-3-carboxamides as glucokinase (gk) activators
AR058892A1 (es) Metodos para tratar lupus cutaneo con el uso de compuestos de aminoisoindolina
WO2002034727A3 (en) Treatment of gastrointestinal stromal tumors
AR054688A1 (es) Alquil-piridinas como inhibidores 11-beta de la diabetes
DE502004003688D1 (de) Pyrazolidin-1,2-dicarbonsäure-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
NO883487L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
HK1048304A1 (en) Novel aminobenzophenones
UA80474C2 (en) Aminoheteroaryl compounds as inhibitors of protein kinase
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
NO20044466L (no) Plasma-karboksypeptidase B-inhibitorer
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
MXPA05013034A (es) N-alquinil-2-heteroariloxialquilamidas para uso como fungicidas.
IL181666A0 (en) Indolin-2-one pyridine derivatives, preparation and therapeutic use thereof

Legal Events

Date Code Title Description
FG Grant or registration